Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19
CONCLUSIONS Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization, ICU admission, and mortality compared with usual care.FUNDING Mayo Clinic.
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Ravindra Ganesh, Colin F. Pawlowski, John C. O’Horo, Lori L. Arndt, Richard F. Arndt, Sarah J. Bell, Dennis M. Bierle, Molly Destro Borgen, Sara N. Hanson, Alexander Heyliger, Jennifer J. Larsen, Patrick J. Lenehan, Robert Orenstein, Arjun Puranik, Leig Source Type: research
More News: Biomedical Science | Cancer & Oncology | Coronavirus | COVID-19 | Diabetes | Diabetes Mellitus | Endocrinology | Hypertension | Intensive Care | Statistics